Overview

A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors

Status:
Terminated
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine safety, tolerability and maximum tolerated dose of BMS-863233 in subjects advanced and/or Metastatic solid tumors.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb
Collaborator:
Exelixis